- Published on
Infectious disease and microbiology – Neuropathies, infectious
Infectious neuropathies refer to inflammation or dysfunction of peripheral nerves caused by infectious agents or their toxins, including viruses, bacteria, parasites, and toxin-mediated mechanisms. A key example is Guillain-Barré syndrome (GBS), an immune-mediated neuropathy often triggered by a preceding infection. GBS has an incidence of approximately 1.2–3 cases per 100,000 people and can occur at any age, with peaks in young adults and older individuals. Risk factors vary depending on the cause and include immunosuppression (e.g., HIV/AIDS), advanced age, and exposure to endemic infections such as Lyme disease, leprosy, or Chagas disease. Preventive measures include vaccination (e.g., zoster, rabies, tetanus) and, in specific situations like tick exposure, prophylactic antibiotics.
The pathophysiology differs by condition but often involves either direct infection of nerve tissue or immune-mediated damage. In GBS, a prior infection triggers an immune response that cross-reacts with peripheral nerve components, leading to demyelination (most common) or axonal injury. Infectious causes include viruses such as herpes simplex virus (HSV), varicella zoster virus (VZV), cytomegalovirus (CMV), and HIV; bacteria such as Borrelia burgdorferi (Lyme disease) and Mycobacterium leprae (leprosy); parasites like Trypanosoma cruzi; and toxins from organisms such as Clostridium botulinum and Corynebacterium diphtheriae. Additionally, many cases of GBS are preceded by infections like Campylobacter jejuni, respiratory viruses, or gastrointestinal illnesses.
Clinical presentation depends on the underlying cause. Viral neuropathies often present with pain and dermatomal rashes, as seen in herpes zoster, or progressive sensory and motor deficits, as in CMV or HIV-related neuropathies. Bacterial causes such as Lyme disease may produce cranial nerve palsies, meningitis, or radiculopathy, while leprosy leads to sensory loss and nerve thickening. Toxin-mediated neuropathies have distinctive features, such as descending paralysis in botulism or muscle spasms in tetanus. In contrast, GBS typically begins with ascending symmetric weakness starting in the lower limbs, progressing over days to weeks and potentially involving respiratory muscles and autonomic dysfunction.
Diagnosis relies on clinical evaluation supported by laboratory and imaging studies. Tests may include detection of viral DNA (e.g., CMV in cerebrospinal fluid), serologic testing for Lyme disease, toxin identification in suspected botulism, and cerebrospinal fluid analysis in GBS, which classically shows elevated protein with normal cell count. Imaging such as MRI may demonstrate nerve root enhancement, while nerve conduction studies help assess the extent of nerve involvement.
Management is directed at the underlying cause. Antiviral therapy (e.g., acyclovir for HSV/VZV, ganciclovir for CMV) is used for viral infections, while bacterial causes like Lyme disease are treated with doxycycline or ceftriaxone. Toxin-mediated conditions require antitoxins and supportive care. For GBS, early treatment with plasmapheresis or intravenous immunoglobulin (IVIG) is essential to reduce disease severity and duration. Supportive care, including monitoring for respiratory failure, managing autonomic instability, and rehabilitation, plays a critical role in recovery.
Complications can be significant, particularly in GBS, where patients may experience residual neurologic deficits, recurrence, or prolonged disability. Early recognition and prompt management are crucial to improving outcomes and reducing long-term morbidity.
Infectious neuropathies refer to inflammation or dysfunction of peripheral nerves caused by infectious agents or their toxins, including viruses, bacteria, parasites, and toxin-mediated mechanisms. A key example is Guillain-Barré syndrome (GBS), an immune-mediated neuropathy often triggered by a preceding infection. GBS has an incidence of approximately 1.2–3 cases per 100,000 people and can occur at any age, with peaks in young adults and older individuals. Risk factors vary depending on the cause and include immunosuppression (e.g., HIV/AIDS), advanced age, and exposure to endemic infections such as Lyme disease, leprosy, or Chagas disease. Preventive measures include vaccination (e.g., zoster, rabies, tetanus) and, in specific situations like tick exposure, prophylactic antibiotics.
The pathophysiology differs by condition but often involves either direct infection of nerve tissue or immune-mediated damage. In GBS, a prior infection triggers an immune response that cross-reacts with peripheral nerve components, leading to demyelination (most common) or axonal injury. Infectious causes include viruses such as herpes simplex virus (HSV), varicella zoster virus (VZV), cytomegalovirus (CMV), and HIV; bacteria such as Borrelia burgdorferi (Lyme disease) and Mycobacterium leprae (leprosy); parasites like Trypanosoma cruzi; and toxins from organisms such as Clostridium botulinum and Corynebacterium diphtheriae. Additionally, many cases of GBS are preceded by infections like Campylobacter jejuni, respiratory viruses, or gastrointestinal illnesses.
Clinical presentation depends on the underlying cause. Viral neuropathies often present with pain and dermatomal rashes, as seen in herpes zoster, or progressive sensory and motor deficits, as in CMV or HIV-related neuropathies. Bacterial causes such as Lyme disease may produce cranial nerve palsies, meningitis, or radiculopathy, while leprosy leads to sensory loss and nerve thickening. Toxin-mediated neuropathies have distinctive features, such as descending paralysis in botulism or muscle spasms in tetanus. In contrast, GBS typically begins with ascending symmetric weakness starting in the lower limbs, progressing over days to weeks and potentially involving respiratory muscles and autonomic dysfunction.
Diagnosis relies on clinical evaluation supported by laboratory and imaging studies. Tests may include detection of viral DNA (e.g., CMV in cerebrospinal fluid), serologic testing for Lyme disease, toxin identification in suspected botulism, and cerebrospinal fluid analysis in GBS, which classically shows elevated protein with normal cell count. Imaging such as MRI may demonstrate nerve root enhancement, while nerve conduction studies help assess the extent of nerve involvement.
Management is directed at the underlying cause. Antiviral therapy (e.g., acyclovir for HSV/VZV, ganciclovir for CMV) is used for viral infections, while bacterial causes like Lyme disease are treated with doxycycline or ceftriaxone. Toxin-mediated conditions require antitoxins and supportive care. For GBS, early treatment with plasmapheresis or intravenous immunoglobulin (IVIG) is essential to reduce disease severity and duration. Supportive care, including monitoring for respiratory failure, managing autonomic instability, and rehabilitation, plays a critical role in recovery.
Complications can be significant, particularly in GBS, where patients may experience residual neurologic deficits, recurrence, or prolonged disability. Early recognition and prompt management are crucial to improving outcomes and reducing long-term morbidity.
0 Comments
